The Peritoneal Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Peritoneal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peritoneal Tumor. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peritoneal Tumor and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Peritoneal Tumor by seven companies/universities/institutes. The top development phase for Peritoneal Tumor is phase i with three drugs in that stage. The Peritoneal Tumor pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Peritoneal Tumor pipeline products market are: Enlivex Therapeutics, BioNTech and Sutro Biopharma.
The key targets in the Peritoneal Tumor pipeline products market include Cells Expressing Folate Receptor Alpha (Adult Folate Binding Protein or Folate Receptor 1 or KB Cells FBP or Ovarian Tumor Associated Antigen MOv18 or FOLR1), Cells Expressing Claudin 6 (Skullin or CLDN6), and Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (PI3K-Alpha or Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.1.137 or EC 2.7.1.153).
The key mechanisms of action in the Peritoneal Tumor pipeline product include Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (PI3K-Alpha or Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Prote with one drug in Phase I. The Peritoneal Tumor pipeline products include five routes of administration with the top ROA being Intravenous and six key molecule types in the Peritoneal Tumor pipeline products market including Small Molecule, and Oncolytic Virus.
Peritoneal Tumor overview
Peritoneal tumor is the invasion of the serous membrane lining the peritoneal cavity by malignant cells, that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. The malignant cells originate de novo in the mesothelioma or disseminate from other primary tumor sites.
For a complete picture of Peritoneal Tumor’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
